Background {#Sec1}
==========

Biosynthesis of 17β-estradiol from androgen precursors is catalysed by the enzyme aromatase, which is expressed from the *cyp19* gene and exists in the ovaries, placenta, testes, breasts, brain, fat, liver and muscles \[[@CR1]\]. 17β-Estradiol production and follicular development are controlled by the expression level and activity of aromatase \[[@CR2]\]. During follicular growth, aromatase mRNA expression levels in granulosa cells from dominant follicles and 17β-estradiol levels in the follicular fluid are significantly increased \[[@CR3], [@CR4]\].

Various studies have demonstrated the role of androgens in stimulating follicular development. Androgen receptors (AR) are observed in primary follicles and advanced-stage follicles, and are detected in the granulosa cells of primordial follicles \[[@CR5]\]. Androgens have been shown to stimulate the growth of small antral follicles and inhibit apoptosis of preovulatory follicles in primate ovaries \[[@CR6], [@CR7]\], whereas AR-knockout mice exhibit greatly increased apoptosis of granulosa cells in preovulatory follicles \[[@CR8]\]. Testosterone and dihydrotestosterone (DHT) stimulate the growth of cultured follicles, increase the number of follicles and increase granulosa cell proliferation in mammalian cells \[[@CR6], [@CR7]\]. Testosterone and androstenedione significantly increase the abundance of aromatase mRNA and the accumulation of 17β-estradiol \[[@CR2], [@CR9], [@CR10]\]. However, excessive testosterone is involved in polycystic ovary syndrome (PCOS), which is the most common endocrine disorder in females and is associated with arrested follicular development and the failure to select a dominant follicle \[[@CR11]\]. Deficiency of 1,25-dihydroxyvitamin D~3~ (1,25D~3~), an active form of vitamin D, is a common risk factor in patients with PCOS \[[@CR12], [@CR13]\]. A daily 1,25D~3~ supplement enhances the intestinal absorption of calcium and alleviates both PCOS symptoms and gonadal dysfunction in 1,25D~3~ receptor (VDR)-null mutant mice \[[@CR14]\].

1,25D~3~ plays important roles in calcium homeostasis, bone metabolism, and cell differentiation, proliferation, and apoptosis. Immunohistochemistry assays have demonstrated that VDR localizes to the follicles and predominantly exists in the nuclei of granulosa cells, suggesting that it has some role in reproduction \[[@CR15]\]. Recent studies have demonstrated that aromatase activity and expression level are low in the ovaries of VDR-null mutant mice, but the activity is increased to 60% of wild-type levels by calcium supplementation in the normal range. Circulating 17β-estradiol levels are also low in VDR-null mutant mice and do not rise after calcium supplementation \[[@CR16]\]. Taken together, these results indicate that 1,25D~3~ plays a role in estrogenesis that is only partially mediated by extracellular calcium homeostasis.

It has recently been shown that signalling via 1,25D~3~/VDR-mediated protein tyrosine phosphorylation occurs in bone, intestine, muscle and cancer cells \[[@CR17]\]. The fast nongenomic responses of 1,25D~3~/VDR in muscle cells involve the phosphotyrosine form of a downstream protein, c-Src \[[@CR18], [@CR19]\]. Interestingly, c-Src is also downstream of the estradiol/membrane-associated estradiol receptor (ER) in the stimulation of aromatase activity. The phosphorylation of aromatase at tyrosine 361 is crucial in the up-regulation of aromatase activity through the estradiol/membrane-associated ER and c-Src signalling in mammalian cell lines \[[@CR20]\]. The AR is also localized in the plasma membrane and is associated with Src after testosterone treatment in Sertoli cells \[[@CR21]\].

A gap junction is a type of intercellular connection that enables the transfer of various small molecules and ions between cells. Such transfers between granulosa cells and oocytes have been implicated in playing important roles in follicular development and oocyte growth \[[@CR22]\]. Gap junctions between granulosa cells contain abundant levels of connexin (Cx) 43, which is present at every stage of follicular growth \[[@CR23]\]. The level of Cx43 protein expression increases during follicular development and decreases with follicular atresia \[[@CR24]\]. Oocytes from Cx43-null mice failed to reach meiotic maturation, resulting in infertility \[[@CR24]\]. Wu et al. demonstrated that excess DHT reduces Cx43 expression and impairs communication between granulosa cells \[[@CR25]\]. Additionally, 1,25D~3~ increases Cx43 protein levels and Cx43 mRNA stability via the nuclear VDR in human skin fibroblasts \[[@CR26]\].

However, no studies have investigated the effect of the testosterone and 1,25D~3~ interaction on aromatase expression and phosphorylation in granulosa cells. Additionally, the effects of 1,25D~3~ and testosterone-regulated 17β-estradiol production and intercellular communication in granulosa cells have not been fully elucidated. We therefore investigated the interactions of 1,25D~3~ and testosterone to clarify their effects on aromatase protein expression and tyrosine phosphorylation, 17β-estradiol secretion and Cx43 protein expression in cultured ovarian granulosa cells.

Methods {#Sec2}
=======

Animal preparation {#Sec3}
------------------

Immature female Sprague--Dawley rats were housed in plastic cages and maintained on a 12 h light/12 h dark cycle (light on at 6:00 a.m.) with food and water available continuously. The experimental procedures were consistent with the Guidelines of Animal Use and Care from the National Institute of Health and were approved by the Institutional Animal Care and Use Committee of Taipei Medical University-Wang Fang Hospital, Taiwan. Immature female rats at 23--24 days of age were injected with 15 IU PMSG (Sigma, St. Louis, MO, USA) for 48 h to stimulate the development of preantral follicles to antral follicles, and the ovaries of the animals were removed after the animals were sacrificed.

Granulosa cell culture {#Sec4}
----------------------

The ovaries were cleared from the surrounding fat and oviduct, and punctured with 27-gauge needles in phenol red-free Dulbecco\'s Modified Eagle\'s medium (DMEM)/F12 medium (Invitrogen, Carlsbad, CA, USA), modified as described previously \[[@CR27]\]. Granulosa cells were pelleted by centrifugation at 1000 rpm (4°C, 10 min) and resuspended in phenol red-free DMEM/F12 medium with 0.1% fatty acid-free bovine serum albumin, 1% fetal bovine serum, and 2 μg/mL bovine insulin. The follicular debris was then removed, and the granulosa cell suspensions were filtered through a cell strainer (BD Falcon, Bedford, MA, USA). The cells were plated at a concentration of 2.5 × 10^6^ per well in a 6-well plate and were allowed to attach and grow to confluence for 1 day at 37°C, 5% CO~2~, and 95% air. The cultured cells were then incubated in serum/phenol red-free medium (DMEM/F12 containing 0.1% lactalbumin enzymatic hydrolysate) overnight before the beginning of treatment. The cells were treated with different doses of testosterone (0.01, 0.1 or 1 μg/mL) or testosterone combined with 1,25D~3~ (0.1 μM) in 2 mL of serum/phenol red-free medium for 24 h. Granulosa cells were pretreated with an L-type calcium channel blocker nifedipine (NIF, 10 μM, Sigma, St. Louis, MO, USA) or an intracellular calcium chelator bis-(a-aminophe-noxy)-ethane-N,N,N\',N\'-tetraacetic acid, tetra(acetoxymethyl)-ester (BAPTA-AM, 10 μM, Tocris, Minneapolis, MN, USA) for 30 min, pretreated with 1,25D~3~ for 15 min, and treated with one of three testosterone doses or vehicle for 24 h. At the end of the incubation period, the medium was collected, and the cells were lysed in ice-cold lysis buffer containing 50 mM Tris--HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.1% Triton X-100, protease inhibitors and phosphatase inhibitors. A protein extract from the supernatant was used for western blot analysis.

Western blot {#Sec5}
------------

The protein content of the extracts was determined using the Bio-Rad Protein Assay Reagent. Equal amounts of the protein extract (15 μg) were mixed with loading buffer and subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by transfer to a PVDF (polyvinylidene difluoride) membrane (Millipore, Billerica, MA, USA). After blocking for 1 h with 5% non-fat milk powder in Tris Buffered Saline (25 mM Tris, 135 mM NaCl and 2.5 mM KCl) with 0.05% Tween-20 (TBST), the membranes were incubated overnight with primary antibodies in TBST containing 5% non-fat milk powder and subsequently with horseradish peroxidase (HRP)-conjugated secondary antibody (Millipore, Billerica, MA, USA) in TBST with 5% non-fat milk powder at room temperature for 1 h. For experiments involving re-immunoblotting to different antibodies, the blots were stripped in 0.2 M glycine (pH 2.5) and 0.05% Tween-20 at 80°C for 20 min and then rinsed twice with 0.09 M boric acid (pH 7.4), 0.9% NaCl, and 0.05% Tween-20. The membranes were immunoblotted with different antibodies: aromatase (1:1000, Serotec, kidlington, Oxford, UK), phosphotyrosine (1:5000, Millipore, Billerica, MA, USA), Cx43 (1:1000, Novex, San Diego, CA, USA), estradiol receptor β (ERβ) (1:1000, GeneTex, San Antonio, Texas, USA), VDR (1:1000, GeneTex, San Antonio, Texas, USA), and β-actin (1:10000, Chemicon, Temecula, CA, USA). Immunoreactivity was detected by chemiluminescence autoradiography (ECL kit, Millipore, Billerica, MA, USA) in accordance with the manufacturer's instructions. The protein bands were quantified using the NIH image J Software.

Immunoprecipitation-western blot analysis {#Sec6}
-----------------------------------------

Granulosa cells were lysed in ice-cold lysis buffer containing 50 mM Tris--HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.1% Triton X-100, protease inhibitors, and phosphatase inhibitors. The clarified lysate was immunoprecipitated at 4°C for 4 h in 300 μl of NP40 buffer (150 mM NaCl, 1% NP40, 50 mM Tris--HCl, pH 8.0, protease inhibitors, and phosphatase inhibitors) with anti-aromatase antibody (Serotec, kidlington, Oxford, UK) and protein G (GE Healthcare, Piscataway, NJ, USA). After washing, the immunoprecipitates were boiled, separated by 10% SDS-PAGE, and transferred to PVDF membranes. An Easyblot kit (GeneTex, San Antonio, Texas, USA) was used to decrease the interference caused by the heavy and light chains of the IgG. EasyBlocker was used as a blocking buffer to minimize the background caused by protein G contamination, and an EasyBlot anti-mouse IgG (HRP) was used that specifically reacts with the native form of mouse IgG and does not bind to the denatured form.

Aromatase activity assay {#Sec7}
------------------------

The enzyme aromatase is responsible for the synthesis of estradiol from testosterone. Hence, the effect of 1,25D~3~ on 17β-estradiol secretion by granulosa cells was used as an indicator of aromatase activity (modified by Zaher Merhi et al., 2014) \[[@CR28]\]. To study the effect of 1,25D~3~ on the aromatase activity, granulosa cells were cultured in 24-well culture plates for 24 h to attach to the plate. After 24 h of culture, the cells were treated with testosterone or 1,25D~3~/testosterone (i.e. 1,25D~3~ plus testosterone), the medium was collected at the indicated times (10 min, 30 min, 1 h, 6 h and 24 h), and the 17β-estradiol level was measured. In order to exclude the earlier difference in 17β-estradiol secretion, the culture medium was removed after 18 h and replaced with fresh medium supplemented with testosterone or 1,25D~3~/testosterone for another 6 h (18--24 h) treatment. The medium was collected for the measurement of 17β-estradiol concentrations at 18--24 h after the addition of the testosterone or 1,25D~3~/testosterone.

Radioimmunoassay {#Sec8}
----------------

The cell culture medium was collected and stored at −80°C until the assay was performed. 17β-Estradiol levels were assayed using a Coat-A-Count Estradiol RIA kit (Siemens, Dublin, Ireland) according to the manufacturer's protocol. 1 mL of ^125^I-labeled estradiol and 100 μL samples were incubated in anti-estradiol antibody-coated tubes for 3 h at room temperature. After decanting the mixture and washing the tubes, the radioactivity levels of the tubes were counted in a gamma counter. The counts are inversely related to the amount of 17β-estradiol present in the sample. The intra assay coefficients of variation for assays ranged between 3% and 16%, with a mean of 10.2%. The percentage cross-reactivity of this antiserum was 17α-estradiol: not detectable; estriol: 0.32%; estrone-β-D-glucuronide: 1.8%. The limit and highest of detection of the assay was 0--3600 pg/mL.

3-(4,5-dimethylthianol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay {#Sec9}
----------------------------------------------------------------------------------

Cell viability was measured by a colorimetric MTT reduction assay performed as first described by Mosoman \[[@CR29]\]. Each culture well was incubated in 0.5 mg/mL MTT (Sigma, St. Louis, MO, USA) culture medium followed by incubation for 4 h in 5% CO~2~ at 37°C. The culture medium was then aspirated, and cells were lysed with DMSO. Quantitation of MTT reduction was assayed by measuring the absorbance at 570 nm (against the 630 nm reference) using an ELISA reader (BioTek, Winooski, VT, USA).

RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR) {#Sec10}
-----------------------------------------------------------------------------------------

Total cellular RNA from granulosa cell cultures was isolated using a Total RNA Purification Kit (GeneMark, GMbiolab, Taichung, Taiwan) according to the manufacturer's instructions. RNA concentrations and purity were determined using a NanoDrop ND2000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). First-strand cDNA was synthesized from 300 ng of total RNA using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). The cDNA were used as templates in subsequent qPCR by an ABI 7500 PCR Detection System (Applied Biosystem, Foster City, CA, USA). The primer sequences for Cx43 used for PCR amplifications were as follows: 5′-TTG TTT CTG TCA CCA GTA AC-3′ (antisense) and 5′-GAT GAG GAA GGA AGA GAA GC-3′ (sense). GAPDH was used as the internal control: 5′-CCG CCT GCT TCA CCA CCT TCT-3′ (antisense) and 5′-GTC ATC ATC TCC GCC CCT TCC-3′ (sense). Each reaction contained the RT mixture, primers and SYBR Green Master Mix (Invitrogen, Carlsbad, CA, USA) and was carried out with the following profile: initial heating to 95°C for 10 min followed by 40 cycles of heating to 95°C for 15 s, incubation at 55°C for 30 s and incubation at 72°C for 90 s. Melting-curve analysis and PCR products were run on agarose gels with ethidium bromide staining. Cx43 mRNA levels were normalized to GAPDH and expressed as values relative to the control using the comparative threshold cycle method.

Immunocytochemistry {#Sec11}
-------------------

Granulosa cells were cultured on poly-L-lysine coated coverslips in 6-well plates. After 24 h of treatment, the granulosa cells were fixed in cold 4% paraformaldehyde for 20 min, rinsed three times with phosphate-buffered saline, and permeabilized with 0.1% Triton. Cells were blocked for 1 h with 5% goat serum and incubated for overnight at 4°C with rabbit anti-Cx43 (diluted 1:100, Novex, San Diego, CA, USA). The cells were then incubated for 1 h with FITC-conjugated goat anti-mouse IgG. Nuclei were stained with DAPI. Immunofluorescence images were captured using a confocal microscope (Zeiss LSM 700, Germany).

Statistical analysis {#Sec12}
--------------------

All biochemical data were analyzed with Student's t-test or a one-way analysis of variance (one-way ANOVA). Specific comparisons between any experimental group and a common control group were made using Dunnett's *t*-test. Comparisons between two experimental groups were made using the Student-Newman-Keuls method. Statistical significance was evaluated at the levels of *p* \< 0.05, *p* \< 0.005, and *p* \< 0.001.

Results {#Sec13}
=======

1,25D~3~ attenuated testosterone-induced aromatase expression and increased 17β-estradiol secretion {#Sec14}
---------------------------------------------------------------------------------------------------

To examine whether 1,25D~3~ and testosterone regulate aromatase expression and 17β-estradiol secretion in granulosa cells, we treated cells with 0.1 or 1 μg/mL testosterone or 0.1 μM 1,25D~3~ plus 1 μg/mL testosterone for 24 h. Western blot analysis revealed that both doses of testosterone increased the aromatase levels (*p* \< 0.005; Figure [1](#Fig1){ref-type="fig"}A) compared to vehicle-treated cells, and addition of 0.1 μM 1,25D~3~ resulted in a significant decrease of the 1 μg/mL testosterone-induced aromatase levels (*p* \< 0.005; Figure [1](#Fig1){ref-type="fig"}A). Additionally, treatment with 1,25D~3~ alone attenuated aromatase expression compared to vehicle treatment (*p* \< 0.05; Figure [1](#Fig1){ref-type="fig"}A). We also examined 17β-estradiol secretion using a radioimmunoassay and found that both testosterone-treated groups clearly experienced enhanced 17β-estradiol secretion (*p* \< 0.005; Figure [1](#Fig1){ref-type="fig"}B). The 1,25D~3~/testosterone group exhibited significantly increased 17β-estradiol secretion relative to the group without 1,25D~3~ treatment (*p* \< 0.005). Treatment of cells with 0.1 μM 1,25D~3~ alone for 24 h did not result in a significant increase in 17β-estradiol secretion (*p* \> 0.05; Figure [1](#Fig1){ref-type="fig"}C). These results indicate that 1,25D~3~ has the potential to improve testosterone-induced 17β-estradiol secretion but causes a decrease in testosterone-induced aromatase expression.Figure 1**1,25D** ~**3**~ **attenuated testosterone-induced aromatase expression but improved 17β-estradiol secretions.** Ovarian granulosa cells from rats were pretreated with 1,25D~3~ (0.1 μM) for 15 min and subsequently treated with 0.1 μg/mL or 1 μg/mL testosterone (denoted by T) or vehicle (denoted by −) for 24 h. **(A)** Cells were lysed for protein extraction, and cell lysates were subjected to western blot analysis for aromatase protein detection. The level of aromatase (denoted by Arom) expression was estimated by densitometric analyses after normalization with the β-actin signal (n = 5--6 in each group). **(B and C)** 17β-Estradiol secretions from the granulosa cells were collected from the medium and assessed over the course of a 24-h period of drug treatments. 17β-Estradiol release data were expressed as the fold-change relative to the vehicle-treated control (n = 4--5 in each group). The values represent the means ± SEM. \*\*, *p* \< 0.005 for comparison with the vehicle-treated group; \#\#, *p* \< 0.005 for comparison of testosterone/1,25D~3~ and testosterone alone; a, *p* \< 0.05 for comparison of 1,25D~3~ alone and vehicle-treated group. The values listed within column indicate the means.

1,25D~3~ significantly increased aromatase tyrosine phosphorylation {#Sec15}
-------------------------------------------------------------------

We evaluated whether the phosphorylation of aromatase was regulated by testosterone and 1,25D~3~ using immunoprecipitation-western blot analysis. We determined that the 1,25D~3~/testosterone group exhibited significantly increased the level of aromatase tyrosine phosphorylation at 24 h relative to the testosterone group (*p* \< 0.05; Figure [2](#Fig2){ref-type="fig"}A, left), and 1,25D~3~ alone also significantly increased the level of aromatase tyrosine phosphorylation relative to the control group (*p* \< 0.05; Figure [2](#Fig2){ref-type="fig"}A, right). The left panel in Figure [2](#Fig2){ref-type="fig"}B is a positive control that was both immunoprecipitated and immunoblotted with an anti-aromatase antibody, and the right panel is a negative control for IgG. The lysate of the granulosa cells treated with 1,25D~3~/testosterone showed a significant band attributed to immunoprecipitated aromatase phosphotyrosine and a weak band for IgG.Figure 2**1,25D** ~**3**~ **enhanced testosterone-induced aromatase tyrosine phosphorylation and 17β-estradiol secretion during 18--24 h. (A)** Rat ovarian granulosa cells were treated with vehicle, testosterone, testosterone plus 1,25D~3~ or 1,25D~3~ alone for 24 h (n = 4--5 in each group). Aromatase was immunoprecipitated before being subjected to SDS-PAGE for resolution. The resultant blot was probed using both phosphotyrosine and aromatase antibodies. The expression of aromatase tyrosine phosphorylation (denoted by pTyr-Arom) was normalized to the corresponding aromatase expression and is represented as a percentage relative to the vehicle-treated control. **(B)** The left panel is a positive control that was both immunoprecipitated and immunoblotted with an anti-aromatase antibody. The lysate was also immunoprecipitated with the anti-aromatase antibody or IgG and immunoblotted with an anti-phosphotyrosine antibody, as shown in the right panel. A weak band in the IgG lane is as a negative control. **(C)** Cells were treated with testosterone alone or testosterone plus 1,25D~3~ as indicated for various time periods (n = 4--5 in each group). Each pTyr-Arom level was normalized using the corresponding aromatase level and is represented as a percentage relative to the vehicle-treated control. **(D)** After treatment for various time periods as indicated, the 17β-estradiol production levels were measured by radioimmunoassay. **(E)** After treatment with testosterone alone or testosterone plus 1,25D~3~ for 18 h, the culture medium was removed and then replaced with fresh medium. Cells were continuously treated for another 6 h (18--24 h span). After the final 6 h, medium was collected and the 17β-estradiol secretion levels were measured by radioimmunoassay (n = 6 in each group). The values represent the means ± SEM. \#, *p* \< 0.05; \#\#, *p* \< 0.005 for comparison of the two treatment groups. The values listed within column indicate the means.

We next investigated the time course of the phosphotyrosine response to testosterone and to 1,25D~3~/testosterone. Our data demonstrate that testosterone treatment induced aromatase tyrosine phosphorylation at 10 min, 30 min and 1 h, whereas 1,25D~3~ improved the effect of testosterone at 30 min and increased the duration of the effect to 6 h (*p* \< 0.05; Figure [2](#Fig2){ref-type="fig"}C) and 24 h (Figure [2](#Fig2){ref-type="fig"}A). We also collected the medium for the 17β-estradiol assay and determined that testosterone-induced 17β-estradiol secretion increased at 30 min, 1 h (*p* \< 0.05) and 6 h (n = 5; *p* \< 0.001; Figure [2](#Fig2){ref-type="fig"}D). There was no difference in 17β-estradiol secretion between the testosterone-treated groups and the 1,25D~3~/testosterone-treated groups at up to 6 h (*p* \> 0.05; Figure [2](#Fig2){ref-type="fig"}D). We also collected the medium 18--24 h after drug treatment and found that the 1,25D~3~/testosterone-treated group significantly increased 17β-estradiol secretion (*p* \< 0.05; Figure [2](#Fig2){ref-type="fig"}E). These studies demonstrated that 1,25D~3~ increased aromatase tyrosine phosphorylation and 17β-estradiol secretion.

1,25D~3~ and testosterone-induced 17β-estradiol production was mediated by calcium {#Sec16}
----------------------------------------------------------------------------------

One possible mechanism for 1,25D~3~/testosterone modulation of 17β-estradiol production is through increasing calcium concentrations. We studied whether NIF or BAPTA-AM could inhibit 1,25D~3~/testosterone-regulated 17β-estradiol secretion. A radioimmunoassay of 17β-estradiol production is presented in Figure [3](#Fig3){ref-type="fig"}. Statistical analysis revealed that testosterone doses (0.01, 0.1 and 1 μg/mL) increased 17β-estradiol production (*p* \< 0.001 and *p* \< 0.005), and 1,25D~3~ (0.1 μM) increased high-dose (1 μg/mL) testosterone-induced 17β-estradiol secretion (*p* \< 0.05; Figure [3](#Fig3){ref-type="fig"}A). Our data demonstrate that pre-treatment with NIF reduced 1,25D~3~ and testosterone (0.01 and 1 μg/mL)-enhanced 17β-estradiol secretion in granulosa cells (*p* \< 0.05; Figure [3](#Fig3){ref-type="fig"}A) but not testosterone (1 μg/mL)-induced 17β-estradiol secretion (Figure [3](#Fig3){ref-type="fig"}B). BAPTA-AM reduced 17β-estradiol secretion induced by 1,25D~3~/testosterone (0.01, 0.1 and 1 μg/mL) (*p* \< 0.001; Figure [3](#Fig3){ref-type="fig"}A) and by testosterone (1 μg/mL) alone (*p* \< 0.05; Figure [3](#Fig3){ref-type="fig"}B). We also monitored cell viability using an MTT reduction assay. The viability of cultured cells exposed to NIF (10 μM) or BAPTA-AM (10 μM) did not significant differ from the control group (*p* \> 0.05; Figure [3](#Fig3){ref-type="fig"}C). Thus, these data revealed that chelation of intercellular calcium with BAPTA-AM resulted in suppression of both testosterone- and 1,25D~3~/testosterone-modulated 17β-estradiol secretion, while calcium from the L-type calcium channel was involved in only 1,25D~3~/testosterone-modulated 17β-estradiol secretion in cultured granulosa cells.Figure 3**1,25D** ~**3**~ **and testosterone-induced 17β-estradiol secretion was mediated by calcium accumulation. (A)** Granulosa cells were divided into vehicle, testosterone, testosterone plus 1,25D~3~, L-type calcium channel blocker NIF (10 μM) or intracellular calcium chelator BAPTA-AM (10 μM) pre-treatment groups (n = 4--5 in each group). The individual levels of 17β-estradiol were also assayed using a radioimmunoassay. **(B)** Testosterone-induced 17β-estradiol released by granulosa cells cultured with or without NIF or BAPTA-AM in the absence of 1,25D~3~ was measured (n = 9 in each group). **(C)** After NIF or BAPTA-AM treatment for 24 h, cells were subjected to the MTT reduction assay to measure cell viability. MTT reduction data are expressed as the percentage of values relative to the control group. The measurements were performed in triplicate, and each cytotoxicity experiment was repeated four times. The values represent the means ± SEM. \#, *p* \< 0.05; \#\#, *p* \< 0.005 for comparison of two drug groups; a, *p* \< 0.001 for comparison of 0.1 μg/mL and 0.01 μg/mL testosterone; b, *p* \< 0.05 for comparison of 1 μg/mL and 0.1 μg/mL testosterone. The values listed within column indicate the means.

The effects of testosterone and 1,25D~3~ on ERβ or VDR expression {#Sec17}
-----------------------------------------------------------------

We examined the expression levels of ERβ and VDR in granulosa cells to determine if they were altered by testosterone and 1,25D~3~. Western blot analysis revealed that granulosa cells treated with testosterone (0.1 and 1 μg/mL) exhibited markedly increased ERβ expression levels (*p* \< 0.005; Figure [4](#Fig4){ref-type="fig"}A) and that 1 μg/mL testosterone treatment increased ERβ expression more than treatment with 0.1 μg/mL testosterone (*p* \< 0.05). However, the two doses of testosterone did not alter VDR levels (*p* \> 0.05; Figure [4](#Fig4){ref-type="fig"}B). Additionally, pre-treatment with 1,25D~3~ did not alter testosterone-induced ERβ expression and did not influence VDR expression (n = 3--4, *p* \> 0.05; Figure [4](#Fig4){ref-type="fig"}A, B). Thus, testosterone alone affected ERβ expression, but 1,25D~3~ pre-treatment had no influence on ERβ or VDR in cultured granulosa cells.Figure 4**Testosterone, but not 1,25D** ~**3**~ **, enhanced ERβ expression; testosterone and 1,25D** ~**3**~ **had no effect on VDR expression.** Granulosa cells were pretreated with 1,25D~3~ for 15 min and subsequently treated with one of two testosterone doses or vehicle for 24 h (n = 4--5 in each group). The granulosa cell lysates were subjected to western blot analysis for **(A)** ERβ and **(B)** VDR expression levels. The levels of ERβ and VDR expression were quantified using densitometry and normalized to β-actin. The values represent the means ± SEM. \*\*, *p* \< 0.005 for comparison with the vehicle-treated group. \#, *p* \< 0.05 for comparison of two drug groups. The values listed within column indicate the means.

1,25D~3~ reversed testosterone-induced down-regulation of Cx43 in granulosa cells {#Sec18}
---------------------------------------------------------------------------------

Finally, to examine whether 1,25D~3~ can affect the testosterone-induced down-regulation of Cx43, granulosa cells were treated with testosterone in the presence or absence of 0.1 μM 1,25D~3~. We determined the cellular localization of Cx43 using immunofluorescence and observed its expression as green fluorescent plaques (Figure [5](#Fig5){ref-type="fig"}A). Cx43 protein expression was markedly decreased when cells were treated with a high dose of testosterone (1 μg/mL; *p* \< 0.005), but this effect was reversed by pre-treatment with 1,25D~3~ (*p* \< 0.05; Figure [5](#Fig5){ref-type="fig"}A, B). We performed a real-time PCR analysis and found that cultured cells pre-treated with 1,25D~3~ also reversed testosterone (1 μg/mL)-induced down-regulation of Cx43 (*p* \< 0.05; Figure [5](#Fig5){ref-type="fig"}C). These results indicated that 1,25D~3~ abolishes the inhibitory effect of testosterone on Cx43 expression in granulosa cells.Figure 5**Testosterone-induced down-regulation of Cx43 in granulosa cells was reversed by treatment with 1,25D** ~**3**~ **. (A)** Granulosa cells were treated for 24 h with vehicle, testosterone (0.1 or 1 μg/mL) or testosterone (1 μg/mL) plus 1,25D~3~ (0.1 μM) and fixed in cold paraformaldehyde solution. Cell nuclei were stained with DAPI (left column), and Cx43 levels (green) were examined by confocal microscopy (middle column). The overlay is shown in the right column. **(B, C)** Granulosa cells were treated with 0.01, 0.1, or 1 μg/mL testosterone for 24 h in the presence of vehicle control or 0.1 μM 1,25D~3~. The levels of Cx43 protein and Cx43 mRNA were examined by western blot and qRT-PCR analysis, respectively. The results are expressed as the means ± SEM (n = 4--6 in each group). \*\*, *p* \< 0.005 for comparison with the vehicle-treated group. \#, *p* \< 0.05 for comparison of two drug groups. The values listed within column indicate the means. Scale bars, 10 μm.

Discussion {#Sec19}
==========

Testosterone can induce concentration-dependent physiological and pathological effects. Physiologic levels of testosterone are converted into sufficient 17β-estradiol to improve follicular development, and the pathological effects of testosterone may be due to induced hyperandrogenism and arrested follicular development. Androgen concentrations in the follicular fluid (FF) are higher in small follicles than in large follicles, and the androgen concentration in PCOS FF is higher than in FF from healthy women \[[@CR30], [@CR31]\]. In the present study, we have demonstrated the dose dependence of testosterone-induced aromatase expression (Figure [1](#Fig1){ref-type="fig"}A) and 17β-estradiol secretion (Figures [1](#Fig1){ref-type="fig"}B and [3](#Fig3){ref-type="fig"}A). These results are consistent with a previous report demonstrating that testosterone increases aromatase mRNA levels \[[@CR2]\]. Testosterone increases the levels of aromatase mRNA promoter 1.1- and 1.5-derived transcripts at 1 μM but only increases the promoter 2-derived transcript at the highest (100 μM) dose \[[@CR9]\]. Interestingly, we found that 1,25D~3~ reduced testosterone-induced aromatase expression but stimulated 17β-estradiol secretion (Figure [1](#Fig1){ref-type="fig"}A, B). 1,25D~3~ appears to modulate aromatase expression in the estrogenesis of granulosa cells and has been shown to exert tissue-specific effects on aromatase expression by various promoters \[[@CR32]\]. For example, 1,25D~3~ increases aromatase expression in placental cells and osteoblasts but down-regulates aromatase expression in breast cancer cells \[[@CR33]--[@CR35]\]. Lundqvist et al. also demonstrated that a 1,25D~3~ analogue reduces aromatase expression by promoting dissociation of the co-modulator Williams syndrome transcription factor from the *cyp19a1* promoter in breast cancer cells \[[@CR36]\]. In addition, competition for shared co-regulators between VDR and AR is one possible explanation for the suppressive effect of 1,25D~3~/VDR signals on AR transcriptional activity \[[@CR37]\]. In our study, we found that treatment with 1,25D~3~ alone reduced aromatase expression but did not alter 17β-estradiol secretion (Figure [1](#Fig1){ref-type="fig"}A, C). Thus, 1,25D~3~ exhibits a synergist effect in attenuating testosterone-induced aromatase expression.

Recently, aromatase activity was shown to mediate posttranslational modifications. Changes in aromatase activity often reflect differential protein expression arising from a slow rate of mRNA transcription. The phosphorylation of aromatase rapidly regulates estradiol production. For example, studies of murine aromatase suggest that serine 118 \[[@CR38]\] or tyrosine 361 \[[@CR20]\] can be phosphorylated and affect aromatase stability or activity. Specifically, increases in aromatase activity and estradiol secretion are regulated by c-Src kinase-catalysed tyrosine phosphorylation \[[@CR20]\] and inhibits in aromatase activity by protein tyrosine phosphatase 1B in breast cancer cells \[[@CR39]\]. In our study, although 1,25D~3~ inhibited aromatase protein expression, we also found that it can regulate tyrosine phosphorylation and change the activity of aromatase to improve 17β-estradiol secretion at longer times. We demonstrated that 1,25D~3~ treatment led to a significantly increased aromatase tyrosine phosphorylation level at 30 min, 6 h (Figure [2](#Fig2){ref-type="fig"}C) and 24 h (Figure [2](#Fig2){ref-type="fig"}A, left) compared with testosterone alone (Figure [2](#Fig2){ref-type="fig"}A, C). 1,25D~3~ also increased the level of aromatase tyrosine phosphorylation without testosterone at 24 h (Figure [2](#Fig2){ref-type="fig"}A, right). No difference in 17β-estradiol concentration between the testosterone and 1,25D~3~/testosterone groups was observed within the first 6 h (Figure [2](#Fig2){ref-type="fig"}D), but 1,25D~3~ markedly increased 17β-estradiol secretion at 18--24 h (Figure [2](#Fig2){ref-type="fig"}E). These results might suggest that a sustained, 1,25D~3~-induced increase in aromatase tyrosine phosphorylation maintains the effect of testosterone on 17β-estradiol secretion at 18--24 h. Thus, the 13% increase in 17β-estradiol production might arise at later times during the 24 h treatment with 1,25D~3~. Because VDRs are located in the largest follicles, the 13% increase in 17β-estradiol from 1,25D~3~/testosterone treatment might assist growth of the largest follicles. 1,25D~3~ might in this way inhibit aromatase expression and prevent aromatase excess syndrome, and increased aromatase tyrosine phosphorylation may rapidly regulate 17β-estradiol in the appropriate time frame.

1,25D~3~ is also known to promote calcium absorption from intestinal cells \[[@CR40]\]; however, there was no clear evidence suggesting that 1,25D~3~ increased calcium accumulation in granulose cells. Two different calcium channels (T-type and L-type) are involved in steroidogenesis in granulose cells \[[@CR41]\]. In this study, we observed that an L-type calcium channel blocker reduced 17β-estradiol secretion under 1,25D~3~/testosterone (0.01 or 1 μg/mL) treatment (Figure [3](#Fig3){ref-type="fig"}A). 1,25D~3~/testosterone-induced 17β-estradiol secretion was also significantly reduced by an intracellular calcium chelator. Additionally, NIF (10 μM) or BAPTA-AM (10 μM) alone did not cause cell toxicity (Figure [3](#Fig3){ref-type="fig"}C), and this dose of BAPTA-AM also reduces testosterone-induced 17β-estradiol secretion without 1,25D~3~ (Figure [3](#Fig3){ref-type="fig"}B). These results are similar to a report that implicated a calcium-dependent pathway in mediation of gonadotropin-induced steroidogenesis in the ovary \[[@CR42]\]. Weitzel et al. demonstrated that calcium signals are critical in the inhibition of low-density lipoprotein receptor-1-mediated estradiol production in murine granulosa cells \[[@CR43]\]. Our data is the first to illustrate that stimulation of 17β-estradiol production by 1,25D~3~ and testosterone is mediated by the L-type calcium channel and intracellular calcium levels (Figure [3](#Fig3){ref-type="fig"}).

Several effects of 17β-estradiol have been shown to be important for follicular development and ovarian function, including the regulation of ER levels, stimulation of DNA synthesis, cell proliferation and regulation of atresia in ovarian follicles \[[@CR44]\]. ERβ is the important ER member expressed in growing granulosa cells and the mature follicle in rodent ovaries and is critical to granulosa cell proliferation and differentiation \[[@CR45]\]. We have demonstrated that testosterone-treated granulosa cells exhibited significantly increased ERβ levels and that 1,25D~3~ did not alter testosterone-induced ERβ expression (Figure [4](#Fig4){ref-type="fig"}A). This result is similar to the finding that the expression levels of ERβ mRNA in the ovaries of VDR-null mutant and wild-type mice are the same \[[@CR16]\]. Additionally, both testosterone and 1,25D~3~ had no effect on VDR expression (Figure [4](#Fig4){ref-type="fig"}B). These results might suggest that testosterone or 1,25D~3~/testosterone increases ERβ levels but not VDR levels.

Intercellular and intracellular endocrine regulatory mechanisms may be critical for follicle growth, dominant follicle selection, and follicle atresia. As ovarian follicles grow from the small to the large antral stage, granulosa cells provide 17β-estradiol by aromatase activation for dominant follicle development \[[@CR46]\]. In contrast, other small follicles undergo atresia via apoptosis \[[@CR47]\]. AR is expressed in primordial follicles, advanced-stage follicles and primary follicles \[[@CR5]\], and testosterone stimulates the early stages of follicle growth, inhibits preovulatory follicle apoptosis and limits follicle size \[[@CR6]\]. Thus, the observation that many small follicles grow in PCOS may be explained by excess testosterone. Alternatively, 1,25D~3~ might inhibit the testosterone-stimulated early stages of follicular growth because 1,25D~3~ is known to inhibit the proliferation and induce the differentiation of a variety of cells \[[@CR48]\], and VDR is expressed in the granulosa cells of largest follicle \[[@CR49]\]. It is possible that 1,25D~3~ paired with testosterone preferentially improves the growth of larger follicles. Hence, the effect of 1,25D~3~ and testosterone on aromatase in granulosa cells might indicate a plausible treatment option for PCOS. Several reports have also shown that 1,25D~3~ regulates antimüllerian hormone (AMH) signalling, follicle-stimulating hormone sensitivity, and progesterone production in human granulosa cells, and decreases the abnormally elevated AMH levels in 1,25D~3~-deficient women with PCOS, indicating a critical role for 1,25D~3~ in follicular development \[[@CR50]\].

Intercellular communication via gap junctions is vitally important for granulosa cell differentiation and oocyte growth \[[@CR22]\]. In this study, western blot analysis, qRT-PCR and immunostaining showed that high dose (1 μg/mL) of testosterone decreased Cx43 protein expression in granulosa cells, and this decrease was reversed by co-treatment with 0.1 μM 1,25D~3~ (Figure [5](#Fig5){ref-type="fig"}). These results are similar to the finding that excess DHT down-regulates Cx43 in granulosa cells \[[@CR25]\]. The correlation between abnormal androgen concentrations and Cx43 expression might contribute to the pathogenesis of PCOS, and 1,25D~3~ might prevent Cx43 down-regulation.

Conclusions {#Sec20}
===========

We determined that testosterone treatment increased aromatase expression and increased 17β-estradiol secretion in granulosa cells. 1,25D~3~ decreased testosterone-induced aromatase expression but significantly increased aromatase phosphotyrosine levels and lengthened the duration of testosterone-induced 17β-estradiol secretion in rat granulosa cells to 18--24 h. We also determined that 1,25D~3~/testosterone-induced 17β-estradiol secretion is dependent on changes in calcium levels. Additionally, testosterone increased ERβ expression, but neither 1,25D~3~ nor testosterone mediated VDR expression. Finally, a high dose of testosterone reduced Cx43 expression, and 1,25D~3~ abolished testosterone-reduced Cx43 levels.
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